Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1 4Phase 1/2 3

Status

Terminated 3Completed 3

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Thyroid Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Medullary 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × vandetanib × Clear all
NCT02495103 2021-01-26

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
7 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell

NCT00923247 2018-11-29

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
22 enrolled 21 charts
Head & Neck

Neoplasms, Thyroid Neoplasms, Carcinoma, Medullary

NCT00862836 2016-10-10

ZACFAST

Sanofi

Phase 1/2 Terminated
15 enrolled 13 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡